Ascentage Pharma Group International has announced the successful closing of an offshore placement, resulting in net proceeds of approximately HKD1,492 million (around US$190.1 million). The placement involved the sale of 22 million ordinary shares by the Dajun Yang Dynasty Trust, an affiliate of the company's CEO, Dajun Yang. These shares were sold at a price of HKD68.60 per share. In connection with this transaction, Ascentage Pharma will issue 22 million new ordinary shares to the Vendor at the same price. This newly issued equity represents about 6.29% of the company's share capital prior to the placement. The company plans to use the proceeds to enhance commercialization efforts, expand global clinical development, and improve infrastructure and working capital for its global operations.